Ainos, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Ainos, Inc. (NASDAQ: AIMD) is a dual-platform AI and biotech company that pioneers SmellTech, AI diagnostics, and immune therapeutics; its proprietary AI Nose platform and smell language model (SLM) digitize scents into machine-readable Smell IDs for applications in robotics, smart factories, senior care, semiconductor manufacturing, women's health, and environmental monitoring; the company also develops VELDONA, a low-dose oral interferon targeting rare diseases, autoimmune disorders including primary Sjögren's syndrome and HIV-related oral warts, infectious diseases, and animal health applications such as feline chronic gingivostomatitis. Ainos offers AI Nose hardware and software including patented devices for industrial and healthcare use, VOC point-of-care tests like Ainos Flora for vaginal health and STIs, Ainos Pen portable breath analyzer, and CHS430 for ventilator-associated pneumonia; its biotech portfolio encompasses VELDONA human and pet therapeutics, synthetic RNA technologies, and telehealth-friendly POCT solutions. Founded in 1984 and headquartered in San Diego, California, the company--formerly Amarillo Biosciences, Inc. until its name change in May 2021--operates globally with a focus on the United States, Taiwan, Japan, and Southeast Asia. In recent developments, Ainos reported third-quarter 2025 financial results highlighting expansion of industrial partnerships to six, including a September 2025 distribution agreement with Topco Scientific across the U.S., Taiwan, Japan, and Southeast Asia, and an October 2025 strategic alliance with NEXCOM for integrating AI Nose into industrial edge computing; the company secured a $2.1 million commercial order from ASE Technology in August 2025 for AI Nose deployment in semiconductor manufacturing, debuted its patented AI Nose device in August 2025 targeting SmellTech-as-a-Service subscriptions, and showcased the technology at COMPUTEX 2025 and Automation Taipei 2025 with partners ugo and Kenmec; additionally, Ainos received Taiwan Food and Drug Administration approval in August 2025 for a VELDONA clinical study in primary Sjögren's syndrome starting October 2025, with prior TFDA and IRB clearances for HIV oral warts trials, alongside a GICS reclassification to Technology Hardware, Storage & Peripherals in October 2025.
Ainos Launches Smell AI Study at National Taiwan University Hospital for ER Overcrowding and Respiratory Infection Risk Analysis
VASRO Research Highlights Ainos AI Nose Commercialization Progress and Semiconductor Industry Shift Toward AI-Driven Environmental Intelligence
Ainos Reports First Quarter 2026 Financial Results and Highlights Smell AI Execution Across Semiconductors and Healthcare Infrastructure Markets
Ainos Updates Standard Industrial Classification Code to Reflect Smell AI Business Focus
VASRO: Ainos Expands Smell AI from Industrials into Healthcare Infrastructure, Reinforcing AI Infrastructure Positioning and Multi-Vertical Scalability
Ainos, Inc. (NASDAQ:AIMD) Short Interest Update
Ainos, MacKay Memorial Hospital and Topco Scientific Partner to Advance Smell AI Deployment in High-Risk Hospital Environments
VASRO Research Highlights Ainos' Smell AI Commercial Progress and 2026 Deployment Momentum
Ainos Reports Full Year 2025 Financial Results and Highlights Commercial Momentum Entering 2026
The Wall Street Journal Highlights Emerging "Smell AI" - Ainos Advances Commercial Deployment in Semiconductor Environments
Ainos, Inc. (NASDAQ:AIMD) Sees Significant Decrease in Short Interest
Water Tower Research Highlights Ainos' Scaling Momentum Across Semiconductor Value Chain
Ainos Expands AI Nose Validation in Front-End Wafer Fabs with 200 Targeted Deployments in Q1 2026
Ainos (NASDAQ:AIMD) and Xenetic Biosciences (NASDAQ:XBIO) Head to Head Analysis
Ainos Issues Shareholder Letter on Phased AI Nose Deployment of Up to 20,000 Systems and Scalable Recurring Revenue Opportunity
Ainos Activates Industrial-Scale Deployment Roadmap of Up to 20,000 Units, Advancing AI Infrastructure Integration in Semiconductor Production Environments
Ainos Reports Statistically Significant Interim Efficacy Results from VELDONA Clinical Trial in Feline Chronic Gingivostomatitis (FCGS)
Short Interest in Ainos, Inc. (NASDAQ:AIMD) Rises By 1,959.7%
Ainos Initiates Live AI Nose Deployments within Semiconductor Manufacturing Environments
Ainos (OTCMKTS:AIMD) Shares Down 4.4% – Time to Sell?